海外医药:英硅智能与衡泰生物合作开发创新透脑性NLRP3 抑制剂,复宏汉霖H 股全流通获批准业绩预告:微创机器人:2025 年,公司预计收入同比增长约110%-120%;经调整净亏损不超过2.40 亿元,同比缩窄超过50%。截至1 月21 日,图迈全球范围内累计商业化订单超过180 台,累计商业化装机量已突破120 台。金斯瑞生物科技:联营公司传奇生物CARVYKTI 于截至2025 年12 月...
Source Link海外医药:英硅智能与衡泰生物合作开发创新透脑性NLRP3 抑制剂,复宏汉霖H 股全流通获批准业绩预告:微创机器人:2025 年,公司预计收入同比增长约110%-120%;经调整净亏损不超过2.40 亿元,同比缩窄超过50%。截至1 月21 日,图迈全球范围内累计商业化订单超过180 台,累计商业化装机量已突破120 台。金斯瑞生物科技:联营公司传奇生物CARVYKTI 于截至2025 年12 月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.